Clinical Trial Update: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

View source ↗

Summary

A clinical trial evaluating gut and tumor microbiome in patients with ER-positive, HER2-negative breast cancer across stages II-III to advanced was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: BioCorteX Inc | Conditions: Breast Cancer | Status: TERMINATED